Monopar Therapeutics announced a net loss of $3.9 million for Q1 2026, up from $2.6 million in Q1 2025, driven by increased R&D and administrative expenses. The company highlighted positive Phase 3 trial results for ALXN1840 in treating neurologic Wilson disease, with plans to submit a New Drug Application to the FDA by mid-2026. Monopar has $137.5 million in cash, expected to fund operations through the end of 2027, supporting regulatory, commercial, and development activities. Commercial readiness is underway under new leadership, signaling progress toward potential product launch.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Garmin introduced the G2000 PRIME, a new integrated flight deck designed for high-performance Class I/II piston and electric aircraft. It features large, edge-to-edge touchscreen displays with advanced multi-touch capabilities, faster processors, and...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
The global Reactive Hot Melt Adhesives market is projected to grow from USD 2.02 billion in 2025 to USD 4.29 billion by 2035, at a CAGR of 7.72%. Growth is fueled by regulations limiting solvent adhesives, increased use of polyurethane adhesives in a...
Montero Mining completed drillhole MON-ELV-02 to 625.25 meters at its Elvira Gold Project in Chile, successfully testing its top exploration target. The hole confirmed predicted volcanic and porphyry sequences with extensive pyrite and high-sulphidat...
